Indoco Remedies' Q2 FY 2026-27 Quarterly Results

Result Summary

• Indoco Remedies Ltd reported a 11.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 7.6%.
• Its expenses for the quarter were up by 9.4% QoQ and 7.4% YoY.
• The net profit decreased 70.2% QoQ and decreased 311.4% YoY.
• The earnings per share (EPS) of Indoco Remedies Ltd stood at 2.11 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Indoco Remedies Ltd is a prominent pharmaceutical company in India, primarily engaged in the development, manufacture, and marketing of pharmaceutical formulations for human and veterinary use. The company operates in the healthcare sector and offers a wide range of products, including tablets, capsules, creams, and ointments, catering to both domestic and international markets. Known for its strong emphasis on research and development, Indoco Remedies has established a significant presence in the pharmaceutical industry. The company has been involved in various strategic initiatives to expand its market reach and enhance its product offerings. However, specific details regarding recent major developments, such as mergers, acquisitions, or significant product launches, are not available within the provided data.

Revenue

In Q2FY27, Indoco Remedies Ltd reported a total income of ₹522.14 crores, reflecting an increase of 11.2% compared to the previous quarter (Q1FY27), where the total income was ₹469.68 crores. The year-over-year growth from Q2FY26 is 7.6%, as the total income in that period was ₹485.43 crores. This revenue growth indicates a positive trajectory from both quarter-over-quarter and year-over-year perspectives, suggesting an upward trend in the company's revenue generation. The data indicates that the company's revenue streams have shown resilience and growth over the analyzed periods.

Profitability

Indoco Remedies Ltd's profitability metrics for Q2FY27 present a notable picture. The company reported a profit before tax of ₹24.19 crores, which marks a significant decrease of 68.9% from the previous quarter (Q1FY27), where the profit before tax was ₹77.72 crores. Year-over-year, there is a stark contrast as the company had registered a loss before tax of ₹13.53 crores in Q2FY26. The tax expense for Q2FY27 was ₹4.72 crores, which is 61.6% lower than Q1FY27's tax of ₹12.28 crores. The profit after tax for Q2FY27 stood at ₹19.47 crores, which is a decrease of 70.2% from the previous quarter's ₹65.44 crores. Compared to Q2FY26, where the company posted a loss after tax of ₹9.21 crores, there is a positive shift. Earnings per share for Q2FY27 were ₹2.11, down from ₹7.09 in Q1FY27, but an improvement from a negative ₹1.00 in Q2FY26.

Operating Metrics

The total expenses for Indoco Remedies Ltd in Q2FY27 amounted to ₹535.09 crores, showing an increase of 9.4% from Q1FY27's expenses of ₹489.30 crores. Year-over-year, the total expenses rose by 7.4% from ₹498.43 crores in Q2FY26. This rise in expenses aligns with the increase in total income, yet the profit margins have been affected significantly due to the steeper increase in costs relative to income. The data highlights that while the company has managed to increase its revenue, the cost of operations has also risen, impacting the overall profitability. The financial metrics suggest a need to monitor the balance between revenue growth and expense management closely.